NCT00991198|CompletedPhase 2
Loading search results
Sponsor study identifier
interventional
49
1 country
1
Study Start
September 2009
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
January 2010
Actual (reported)Study Completion
January 2010
Actual (reported)This study is an evaluation of the role of topical dissolved oxygen to lessen visible signs of photodamage using a select regimen of topical dissolved oxygen containing cosmeceutical products. Evaluation of the overall skin tolerability of topical dissolved oxygen (safety) utilizing the regimen of products.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
January 2010
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
September 2009
Date type not reportedThis date has not been verified as actual or estimated.
October 6, 2009
Actual (reported)October 7, 2009
Actual (reported)January 2010
Actual (reported)January 2010
Actual (reported)skin grading evaluation of photodamage
8 weeks
stratum corneum hydration (skin capacitance)
8 weeks
bioinstrumental assessment of skin "melanin" lightening, and lesional erythematous sites
8 weeks
bioinstrumental assessment of skin texture, scaliness (desquamation)
Aria Regimens 0.5% conc
Aria Regimen (5 products) 0.25% conc
Aria Regimen Control without O2
0.5% concentration of Topical oxygen
0.25% concentration topical oxygen
Dermatology Consultants Inc
High Point, North Carolina, 27262, United States
Zoe D Draelos, MD
Dermatology Consultants Inc.
49 participants (actual enrollment reported by the registry).
First Submitted
October 6, 2009
First Posted
October 7, 2009
Study Start
September 2009
Date type not reportedThis date has not been verified as actual or estimated.
The Effect of Oxygen Therapy on 6MWD in PAH and CTEPH Patients With Hypoxemia
8 weeks
punch biopsy histopathologic examination (H&E, and immunohistochemistry for Aquaporin 3, and Filaggrin)
8 weeks
RT-PCR collagenase , and hypoxia-inducible factor-1 alpha
8 weeks
no O2
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Primary Completion
January 2010
Actual (reported)Study Completion
January 2010
Actual (reported)Last Updated
June 8, 2011
Record last verified: 2011-06
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: